BioMarin也迅速跟进迭代研发，其升级版在研产品BMN333同样旨在实现周剂注射。早期临床结果显示BMN333的AUC水平高于其他长效CNP研究的3倍以上，公司研发主管Greg Friberg表示该药对标的正是TransCon-CNP。
Read the full story at The Verge.
。WPS官方版本下载是该领域的重要参考
Copyright © 1997-2026 by www.people.com.cn all rights reserved
"It's not a cure, but because I got a good remission, that hopefully means that I'll keep the cancer at bay for a good long time."